European Journal of Neurology

Papers
(The H4-Index of European Journal of Neurology is 40. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
144
Clinical and Genetic Reassessment in Patients With Clinically Diagnosed Hereditary Polyneuropathy97
Concerns Regarding “Small Fiber Morphology and Function in Inclusion Body Myositis—A Multimodal Assessment Including Confocal Corneal Microscopy”95
95
Issue Information89
Structural correlations between brain magnetic resonance image‐derived phenotypes and retinal neuroanatomy88
Central nervous system crystal‐storing histiocytosis: A case report and literature review81
ePoster76
Contribution of Polygenic Scores to Progression Independent of Relapse Activity in Multiple Sclerosis73
CCR5‐Δ32polymorphism—a possible protective factor from gait impairment amongst post‐stroke patients71
Lessons from the past to understand the future71
Clusters of Comorbidities in Multiple Sclerosis and Their Influence on Healthcare Resource Usage68
Out‐of‐hospital versus in‐hospital status epilepticus: The role of etiology and comorbidities63
Neuropathy in GAA‐FGF14 Late‐Onset Cerebellar Ataxia (SCA27B): Prevalence and Characteristics57
COQ2 and SNCA polymorphisms interact with environmental factors to modulate the risk of multiple system atrophy and subtype disposition54
The 2022 European postgraduate (residency) programme in neurology in a historical and international perspective53
Ischaemic cerebral small vessel disease caused by adenosine deaminase 2 deficiency syndrome53
Hearing impairment and development of parkinsonism and possible rapid eye movement sleep behaviour disorder: A CLSA prospective population‐based study51
Basal ganglia ischaemic infarction after thrombectomy: cognitive impairment at acute stage50
Altered grey matter integrity and network vulnerability relate to epilepsy occurrence in patients with multiple sclerosis49
Cost‐effectiveness of acceptance and commitment therapy for people living with motor neuron disease, and their health‐related quality of life49
Levodopa–entacapone–carbidopa intestinal gel: Data from the Swedish national registry for Parkinson's disease48
Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study47
Neurovascular Involvement in Fibromuscular Dysplasia: A Clue for Reappraisal of Old Classifications46
Progressive multifocal leukoencephalopathy in a patient with relapsing multiple sclerosis treated with ocrelizumab: A case report45
Prioritization process for European Academy of Neurology clinical practice guidelines44
Comparative features and outcomes of major neurological complications of COVID‐1944
Electroencephalography functional connectivity—A biomarker for painful polyneuropathy43
Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo‐controlled, dose‐finding trial followed by 24 months of treatment43
The effect of influenza vaccination on the rate of dementia amongst older adults43
Advancements in targeted therapies for generalized acetylcholine receptor antibody positive myasthenia gravis: Beginnings of a paradigm shift43
Diagnostic accuracy of nerve excitability and compound muscle action potential scan derived biomarkers in amyotrophic lateral sclerosis42
Comparing humoral immune response to SARS‐CoV2 vaccines in people with multiple sclerosis and healthy controls: An Austrian prospective multicenter cohort study42
Neurological phenotype of adenosine deaminase 2 deficient patients: a cohort study41
Muscle microRNAs in the cerebrospinal fluid predict clinical response to nusinersen therapy in type II and type III spinal muscular atrophy patients41
The microbiome–gut–brain axis in epilepsy: pharmacotherapeutic target from bench evidence for potential bedside applications40
Response to erenumab assessed by Headache Impact Test‐6 is modulated by genetic factors and arterial hypertension: An explorative cohort study40
Risk factors, neuroimaging correlates and prognosis of the motoric cognitive risk syndrome: A population‐based comparison with mild cognitive impairment40
Markers of Giant Cell Arteritis in Patients Presenting With Ischemic Stroke: A Scoping Review40
Switching from ligand to receptor anti‐calcitonin gene‐related peptide (CGRP) antibodies or vice versa in non‐responders: A controlled cohort study40
0.11661982536316